Durable Remission Seen in Two CLL Patients After CAR T Cell Therapy

TUESDAY, Feb. 15, 2022 -- Long-term chimeric antigen receptor (CAR) T cell signaling and persistence has been demonstrated at more than 10 years after infusion in two chronic lymphocytic leukemia (CLL) patients, according to a study published online...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news